Synageva gets new investors
US privately-held Synageva BioPharma has added two new investment groups as part of the second closing of its financing. This transaction follows the initial funding of $30.0 million announced on April 15. The total financing raised between the two closings is more than $33.0 million. The new investor groups participating in the second closing are Yasuda Enterprise Development, based in Tokyo, Japan, and Hunt BioVentures, located in Dallas, Texas.
Yasuda is one of the largest and most-experienced venture capital firms in Japan. With more than $900.0 million currently under management, Yasuda has supported more than 200 initial public offerings since its inception, said Synageva.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze